Almonty specializes in acquiring distressed and underperforming operations and assets in tungsten markets. These then benefit from the company’s in-house operational experience and unrivalled expertise in the tungsten market.

Highly regarded as a hands-on, turnaround investor-operator, Almonty is an expert at overseeing projects regarded as too complex or difficult for the average, pure ‘financial investor’.

To date, the results of its acquisitions have been fast and very profitable turnarounds. Almonty is actively pursuing other growth opportunities via acquisitions where it can apply its tungsten expertise to create additional value for all stakeholders.

More Information: https://almonty.de/

Altech Advanced Materials AG focuses on innovations in the field of lithium-ion battery technology. Organizationally, the Heidelberg-based company is set up as a participation company focusing on raw material extraction and processing, chemicals, the manufacture of all types of packaging and paper products, and their distribution.

In December 2020, the Heidelberg-based company acquired 25% of the shares in Altech Industries Germany GmbH („AIG“). The major shareholder is Altech Chemicals Australia Pty Ltd (ATC), in which Altech Advanced Materials AG in turn holds an interest. The Australians and the German subsidiary are planning to set up a pilot production plant for the manufacture of the coating material for battery anodes in eastern Germany.

More information: https://www.altechadvancedmaterials.com/

Aspermont has a consolidated position as the leading media services provider to the global resource sectors. Aspermont brands such as Mining Journal and Mining Magazine have served the mining industry with high value content for 185 years and 110 years respectively building loyal and premium quality audiences.

Early in the internet age, Aspermont became a digital pioneer and successfully established one of the first media paywalls in 2002 and then developed semantic search architecture in 2008.

Over the past 20 years, Aspermont has achieved significant competitive advantage as a global rather than regional media services provider, prompting the exit of regional competitors on several continents.

Aspermont has entered a major growth phase in B2B media, driven by technological innovation able to expand the product range geographically and by sector to serve a global audience growing at 30% each year.

Today Aspermont is clearly the leading media services provider to the global mining and energy sectors with a growing presence in agriculture.

Aspermont’s media credentials have been established over two centuries of continuous service to the mining sectors and are unchallenged today. As Mining Journal has been published in London for 185 years and Mining Magazine for 106 years, Aspermont owns the longest established global brands in the mining and energy sectors.

In Australia, Aspermont has been at the forefront of B2B media developments across a number of sectors and with Australia’s Mining Monthly and MiningNews.net being outright leaders in mining.

More Information: https://www.aspermont.com/

Speaker at IIF is Alex Kent, CEO Aspermont Ltd.

*CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore

The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific and Business Advisory Boards comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs.

Cardiol has received clearance from the U.S. FDA for its Investigational New Drug (IND) application that is being investigated in a Phase II/III outcomes study (the LANCER Trial). A double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx, as a cardioprotective therapy to reduce mortality and major cardiovascular events in patients hospitalized with COVID-19 who have a prior history of, or risk factors for cardiovascular disease (CVD), and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

CardiolRx is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC free (<10 ppm).

Cardiol has also received clearance from the FDA for its application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age, In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure – a leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

The Company has research collaborations focused on developing a subcutaneous cannabidiol formulation for heart failure underway at international centers of excellence, including the Houston Methodist DeBakey Heart & Vascular Center, the University of Alberta, and TecSalud del Tecnológico de Monterrey, Mexico.

More Information: https://www.cardiolrx.com/

Speaker at IIF is David Elsley – CEO Cardiol Therapeutics Inc.

*CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore

Defence Therapeutics are Canadian scientific pioneers on a journey to uncover enhanced treatment solutions for future generations through biopharmaceutical innovations. Leading the way with targeted science, strategic products and bold curiosity, we are uncovering micro and macro level methods, bringing catalytic change to future patients.

With the patented Accum technology, Defence Therapeutics offers a platform for so-called antibody-drug conjugates (ADC). In this process, a specific active ingredient is linked to an antibody by means of a peptide linker and thus reaches precisely where it is supposed to act. For example, into a tumor cell. Defence Therapeutics has data showing that Accum can significantly increase the efficacy of certain forms of therapy in combination with immune checkpoint inhibitors. Immune checkpoint inhibitors are targeted in oncology to block anti-inflammatory immune checkpoints to provide benefits during therapy.

More Information: https://defencetherapeutics.com/

Speaker at IIF is Dr. Moutih Rafei, Lead Scientist, VP Research & Development and Director

*CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore

Defense Metals has an indicated mineral resource of 4,890,000 tonnes averaging 3.02% LREO (Light Rare Earth Elements), and inferred resources of 12,100,000 tonnes averaging 2.90% LREO.

Defense Metals Corp. is a mineral exploration company focused on the acquisition of mineral deposits containing metals and elements commonly used in the electric power market, military, national security and the production of “GREEN” energy technologies, such as, high strength alloys and rare earth magnets. Defense Metals has an option to acquire 100% of the 1,708 hectare Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada.

Defense Metals Corp. trades in Canada under “DEFN” on the TSX Venture Exchange, the United States, under “DFMTF” on the OTCQB and the German, Frankfurt Exchange under “35D”

More information: https://defensemetals.com/

Speaker at IIF is Craig Taylor,
CEO of Defense Metals Inc.

* CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore

Desert Gold Ventures Inc. is a gold discovery and development company actively engaged in commercial exploration and gold resource development on the African continent. The company holds two gold exploration permits in Western Mali; its flagship 440km² Senegal Mali Shear Zone Project and the Djimbala project. It also controls the Anumso gold project in Ghana’s Ashanti Belt and the Rutare gold project in central Rwanda.

More information: https://www.desertgold.ca/

Speaker at IIF ist Jared Scharf, CEO

* CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore

dynaCERT is a growing energy sector company that specializes in delivering Carbon Emission Reduction Technologies to a global marketplace.

Throughout years in business, dynaCERT has worked to provide a reliable and effective electrolysis unit that would generate hydrogen and oxygen on demand to: (A) address the growing requirements to reduce emissions; and (B) provide an increase in fuel economy.

By partnering with expert scientific engineers along with a dedicated product development team, dynaCERT overcame critical engineering challenges and successfully completed positive field studies with our HydraGEN HG1 unit. Proven to deliver results, the HydraGEN HG1 continues to be sold in North America and abroad.

dynaCERT has created global interest with our abilities to enhance product development into additional market platforms and deliver a return on investment (ROI). We continue to expand our partnerships with industry leaders, major corporations, private companies and government bodies. These relationships are strengthening our international presence and helping pave the way for technological expansions into rail, marine, oil/gas, stationary generator and mining applications. dynaCERT is in the move.

Our future is exciting. Our perspective is global. Our mission is achievable.

Mor information: https://dynacert.com/

Speaker at IIF ist Jim Payne, CEO dynaCERT Inc.

EPTI AB, founded in 2017 in Stockholm, is an investment and services company in the high-growth areas of gaming, fintech, marketplaces, SaaS and digitalization/IT services. In line with the guiding principle „We empower innovation – A company builder for founders, by founders“, EPTI invests predominantly in majority stakes with an active hands-on approach or co-founds and finances joint ventures with successful entrepreneurs in the high-growth areas of business process digitalization and end-user applications. EPTI Group’s particular strength is to provide growth companies with state-of-the-art technologies, IT/SW human resources, and management and marketing services to develop innovative companies and future gamechangers/market leaders. Currently, the investment portfolio includes more than 25 companies in seven European countries, in which the approximately 200 employees and IT specialists are organized in majority shareholdings.

More information: https://epti.com/

Speaker at IIF is Arli Mujkic, CEO EPTI AB

* CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore

More information: https://firsthydrogen.com/

Speaker at IIF is Nicholas Wrigley, Chairman First Hydrogen UK

* CEST = Frankfurt, Paris | EST = New York, Toronto | HKT = HongKong, Perth, Singapore